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FOOTNOTES  
1 The abbreviations used are PCA, protocatechuic acid; PCD, protocatechuate 
3,4-dioxygenase (protocatechuate: oxygen 3,4-oxidoreductase, EC 1.13.11.3); 
HINANO, 2-hydroxyisonicotinic acid N-oxide; 3-FHB, 3-fluoro-4-hydroxybenzoic 
acid; 3-C1HB, 3-chloro-4-hydroxybenzoic acid; C1NANO, 2-chloroisonicotinic 
acid N-oxide; NANO, nicotinic acid N-oxide; INANO, isonicotinic acid N-oxide; 
MINANO, 2-mercaptoisonicotinic acid N-oxide; 3-XHB, 3-halo-4-hydroxybenzoic 
acid. 
This work was supported by Grant GM 23474 from the National Institutes of 
Health. 
To whom correspondence should be addressed. 
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ABSTRACT  
The binding of 2-hydroxypyridine N-oxide (HYPNO) and a series of structural 
analogs to protocatechuate 3,4-dioxygenase (PCD) has been investigated using 
kinetic and spectral techniques. HYPNO binds less tightly to PCD than 
2-hydroxyisonicotinic acid N-oxide (HINANO), a compound designed to mimic struc-
tural features of species along the PCD reaction pathway, which we have previ-
ously shown to bind to the enzyme in a kinetically irreversible manner [J. Biol. 
Chem. 257, 12746-12751 (1982)]. HYPNO was found to be a time-dependent inhi-





ation (3 x 10
-4 
sec -1 ) of HYPNO were found to be four orders of magnitude less 
than those for 3-fluoro-4-hydroxybenzoic acid (3-FHB) the best freely reversible 
competitive inhibitor of PCD. Although inhibition by HYPNO is not freely reversi-
ble, it can be slowly reversed by a simple displacement with 3-FHB. This is in 
contrast to the inhibition by HINANO whose binding to PCD is reversed only by 
denaturing the enzyme. The displacement of HYPNO by 3-FHB was examined spectro-
photometrically and found to consist of rapid formation of a species which is 
spectrally distinct from the complex of PCD with either inhibitor alone, followed 
by a slow change to give the spectrum of the PCD•3-FHB complex. Analysis of the 
inactivation and spectral data, along with determination of the concentrations of 
both inhibitors immediately after the initial rapid change, is consistent with 
formation of a ternary PCD-HYPN0.3-FHB complex. The initial binding and time-
dependence of inhibition of a series of related ring substituted pyridine N-oxides 
were also studied. The presence of a ketonizable group adjacent to the N-oxide 
causes slow, tight binding of the type seen with HYPNO and HINANO. The spectral 
characteristics of the complexes of HYPNO and HINANO with PCD differ markedly 
from those of the halohydroxybenzoate•PCD complexes and this may reflect differ-




Among the reactions catalyzed by dioxygenases is the oxygenolytic cleavage 
of aromatic rings, and the mechanism of this process is a subject of much current 
interest. One of these enzymes, protocatechuate 3,4-dioxygenase (PCD)
1 , which 
catalyzes the intradiol cleavage of protocatechuic acid, has been isolated from 
a number of microbial genera (Stanier & Ingraham, 1954; Wells, 1972; Hou et al., 
1976; Durham et al., 1980; Bull and Ballou, 1981), with the crystalline enzyme 
from Pseudomonas aeruginosa being the most extensively studied (Fujisawa & Hayaishi, 
1968). One method of investigating the enzymatic mechanism is by studying the 
interaction of various types of inhibitors with the enzyme active site. We, and 
others, have studied the 3-halo-4-hydroxybenzoates and have found them to be potent 
rapidly reversible PCD inhibitors (May et al., 1978; May & Phillips, 1979; Felton 
et al., 1978; Fujisawa et al., 1971; Fujisawa et al., 1972a; Fujisawa et al.,1972b; 
Que et al., 1977; Keyes et al., 1978; Tatsuno et al., 1978; Nakata et al., 1978). 
When complexed with these inhibitors,the enzyme gives a characteristic spectrum with 
a visible maximum at 420 nm. Kinetic and resonance Raman investigations carried out 
in this and other laboratories, have provided evidence that in the initial binding 
step, the p-OH of substrates or inhibitors interacts directly with the essential 
iron atom of the enzyme via Fe-0 ligation. In the case of substrates, subsequent 
ketonization of the m-OH allows oxygen attack at the adjacent carbon to give an 
a-ketohydroperoxide, followed by collapse to product (Scheme I). 
In order to obtain further support for this mechanism we have recently 
studied a compound designed to mimic the ketonized transient species, (VI) along 
the reaction pathway (May et al., 1982). This compound, 2-hydroxyisonicotinic 
acid N-oxide (HINANO, VIIa) was found to be an extremely potent, kinetically irreversi-
ble inhibitor and an active site titrant, although it is not a substrate for PCD. 
Furthermore, denaturation of the enzyme•HINANO complex released virtually all of 










to the enzyme is unlikely. Inhibition with similar characteristics has been 
observed in studies with "transition state analogs" of various enzymes (Frieden 
et al., 1980; Wolfenden, 1976). The spectrum of the enzyme•HINANO complex was 
found to resemble that reported by Bull et al., (1981) for an "ES0 2 " transient 
oxygenated intermediate detected in stopped-flow studies under hyperbaric oxygen 
conditions. 
A detailed kinetic description of the interaction of hydroxypyridine 
N-oxides with PCD would provide a basis for contrasting the binding characteris- 
tics of these compounds to those of ground state inhibitors and substrate analogs. 
However, kinetic analysis of the interaction of PCD with HINANO using standard 
techniques is not feasible due to the kinetic irreversibility of inhibition by 
-5- 
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this compound. We have, therefore, undertaken a detailed study of the inter-
action of PCD with 2-hydroxypyridine N-oxide (HYPNO,VIId). HYPNO retains the 
structural resemblance to the transient species VI but lacks a para carboxylate. 
By analogy to substrate analogs and ground state inhibitors (Que et al., 1977) 
we therefore expected that HYPNO binding to PCD would exhibit a greater degree 
of reversibility, thus allowing a detailed kinetic analysis. Furthermore, we 
wished to examine various related pyridine N-oxides (VII b,c,e), in order to 
assess the effects of ring substituents on binding to the PCD active site. Our 
results provide insight into the details of the interaction of these compounds, 
and of halohydroxybenzoate inhibitors, with the active site PCD. 













a H I NANO OH COOH H 
b 'NAND H COOH H 
c CI NANO Cl COOH H 
d HYPNO OH H H 
e NANO H H COON 
f M I NANO SH COOH H 
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MATERIALS AND METHODS  
All commercial materials were the highest grade obtainable. Protocatechuic 
acid, HYPNO, nicotinic acide N-oxide (NANO), and 3-chloro-4-hydroxybenzoic acid 
(3-C1HB) were recrystallized from water. Isonicotinic acid N-oxide (INANO) was re-
crystallized from methanol. HINANO and 2-chloroisonicotinic acid N-oxide (CINANO) 
were synthesized and purified as described previously ( May et al., 1982). 3-Fluoro- 
4-hydroxybenzoic acid (3-FHB) was synthesized as previously described (May et al.,1978). 
Protocatechuate 3,4-dioxygenase was isolated from 4-hydroxybenzoate-induced cells of 
Pseudomonas  species ATCC 23975 as described previously (May et al., 1978). 
Synthesis of 2-Mercaptoisonicotinic Acid N-oxide (MINANO) 
MINANO was synthesized by the following procedure, based on the general 
method of Taylor and Driscoll(1960). Into a flask, previously evacuated and 
filled with argon, 8.85g (0.123 mol) of KHS (Alfa Chemical Co.) was weighed. 
The contents of the flask were kept under an atmosphere of argon throughout the 
experiment. The flask was fitted with a reflux condenser and 84 ml of methanol 
(absolute) was added. This addition resulted in a clear olive-green solution. 
At reflux,4.12g (.0238 mol) of purified 2-chloroisonicotinic acid N-oxide was 
added and a milky-lime colored mixture resulted. The reaction mixture was 
refluxed for 21 hours with continuous stirring. A mixture with a clear lime 
colored top layer, a middle layer of white solid, and a bottom layer of yellow-
ish-green solid resulted. The remaining methanol was removed by vacuum distil-
lation leaving a yellow and white solid. The solid was dissolved in 60 ml of 
distilled-deionized water. The resulting green solution was acidified with 
concentrated HC1 and chilled at 4° C. The resulting yellow solid was then 
filtered with a buchner funnel. The crude solid was dissolved in a minimal 
amount of hot distilled deionized water and immediately filtered. The filtrate 
was stored overnight at 4°C. The yellow-gold crystals were collected on a 
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buchner funnel and vacuum dried. This recrystallization resulted in 1.64g 
of MINANO. The MINANO was shown to be pure by NMR (D 20, 5% NaOD, 3-(trimethyl-
silyl)propionic acid, Na salt as internal standard: multiplet at 8.136, 2H; 
multip let at 7.326, 1H); mass spectrum (m/e 171 molecular ion) and ele-
mental analysis (calculated:C, 42.10%, H, 2.94%, N, 8.18%, S, 18.73%; found: 
C, 42.10%, H, 2.96%, N, 8.12%, S, 18.73%). The purified MINANO was stored 
under argon to prevent decomposition. 
Dialysis of PCD•HYPNO Complex  
A two ml sample of a solution containing PCD (320 nM) and HYPNO 
(91 pM) in 0.05 V Tris•HC1, pH 7.5, buffer was placed in an Amicon 
ultrafiltration unit (model 8MC) and dialyzed against 0.05 M Tris•HC1, pH 7.5, 
buffer until 20 ml of effluent were collected. The retentate was removed and 
the enzyme activity was assayed and compared with the activity of both the 
undialyzed PCD•HYPNO solution and the PCD solution before addition of HYPNO. 
The activity was measured spectrophotometrically by following the decrease in 
absorbance at 290 nm of a 0.4 mM protocatechuic acid solution in 0.05 M 
Tris•HC1 buffer, pH 7.5 (Stanier & Ingraham, 1954). 
Measurement of Apparent K i 's 
The K 's for HYPNO, NANO, INANO, and CINANO were determined by measuring 
PCD activity using a YSI Model 53 oxygen monitor equipped with a Clark polaro-
graphic electrode and thermostatted to 25°C. The decrease in dissolved oxygen 
with time was recorded and initial rates measured graphically. All inhibitors 
showed a slope effect on the double reciprocal plot and IC I values were estimated 
from the ratio of slopes of the inhibited and uninhibited data. The K 1 for 
HINANO was measured spectrophotometrically using a stopped-flow apparatus to 
examine the initial rate of substrate oxidation at 290 nm as previously 
described (May et al., 1978; May & Phillips, 1979). 
-9- 
MAY/FELTON 320445583 
Calculation of First Order Rate Constants  
A reiterative non-linear least squares program (Duggleby, 1981) was used 
to fit the data to the equation In (A co -At ) = In (k-A0 ) - kt. 
Spectral Studies of the Binding of HYPNO to PCD  
The absorbance at 437 nm of an enzyme solution 11.76 11M in active 
sites in 0.05 M Tris•HC1, pH 7.5 at 25 ° C was followed upon the addition of 
HYPNO in ratios of 4:1, 10:1, and 20:1 HYPNO to active sites. Initial rates 
of change were calculated based on a AE of 514.6 M
-1 cm
-1 and second order 
rate constants were calculated from these initial rates. 
Dialysis Binding Experiments  
In these experiments the appropriate amount of enzyme was dialyzed 
against 0.05 M Tris-HC1, pH 7.5 at 25 0C in an Amicon Ultrafiltration unit fitted 
with an XM100A membrane until the effluent contained no significant absorbance 
at the wavelengths of interest. The appropriate amount of HYPNO was then added 
to the enzyme solution and that solution immediately removed from the unit. 
The solution was diluted to volume with washes from the Amicon unit and incu-
bated for 30 min at room temperature. The appropriate amount of 3-FHB or 
3-C1HB was then added and the solution was immediately returned to the Amicon 
unit and filtered under pressure. The effluents were obtained 3 to 4 min after 
the addition of the halohydroxybenzoate inhibitor. The concentration of HYPNO and 
halohydroxybenzoate in the effluent were determined from absorbances at two 
different wavelengths by the solution of simultaneous equations. For HYPNO 
and 3-FHB, -265 E 	(HYPNO) 388 M -l cm-1 , £ 265 (3-FHB) = 6210 M-l cm-1 , £ 315 (HYPNO) = 
5121 M-l cm-1 , and £ 315 (3-FHB) = 94 M-l cm-1 were used. For HYPNO and 3-C1HB 
6276 (HYPNO) = 677 M -l cm-1 , £ 276 (3-C1HB) = 7362 M-l cm-1 , 6 314 (HYPNO) = 5052 M -1 
cm 
-1
, and 6 314 (3-C1HB) = 625 M -1 cm-1 were used. Since HYPNO binding has 
-1 0- 
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reached equilibrium 30 min following the addition of HYPNO, it can be assumed 
that the solution species are E + HYPNO---"E HYPNO. Upon addition of 3-FHB, 
equilibrium is rapidly established with the enzyme species . Since 3-FHB binds 
more rapidly to E than E•HYPNO (relative k on 's), the enzyme species after ad-
dition of 3-FHB are E•3FHB, E-HYPN0.3FHB, and E•HYPNO when both inhibitors and 
enzyme active sites are present at equal concentrations. The 3-FHB concen-
tration is measured directly, the [E•HIPNO]=[3-FHB], and [E-HYPNO.3FHB] 
[E]total - [3FHB] - [HYPNO]. Therefore KD (2). s can be calculated equal to 
[3FHB][E•HYPN0] 	T
he same method was used to calculate the K D 
for the dissoci- 
[E•HYPNO.3FHB] 
ation of 3-C1HB from the ternary complex. 
KD
(1) 's for the dissociation of HYPNO from E•HYPNO can also be calculated 
from the 1:1:1 dialysis data as the addition of halohydroxybenzoate does not 
affect the E, HYPNO equilibrium within the time of the experiment. The [HYPNO] 
can be measured directly and [E•HYPNO] assumed to be [El total - [HYPNO]. Like- [E ] total 
 [E] is assumed to equal [HYPNO]. K D (1) is therefore calculated according 
to the equation KD = [E][HYPNO]  
[E•HYPNO] 
Henderson Plot  
Initial rates were determined using stopped-flow where enzyme and inhibitors 
were preincubated 75 min before flowing against substrate. The stopped-flow 
accessory of a DW-2 spectrophotometer (Aminco) maintained at 25 °C was used to 
mix 43 nM enzyme active sites inhibited by HYPNO after preincubating 75 min 
at ratios of 35:1 to 600:1 HYPNO:active sites with 60 pM PCA. Both solu- 
tions were in 0.05 M TriS'•1C1, pH 7.5 at 25 °C and final concentrations were one-
half those stated. A
290 
was followed in the dual beam mode with the reference 






Spectrum of the Anaerobic PCD•HINANO Complex  
A closed system was used consisting of a quartz cuvette containing 15 pl 
of PCD (149 uM) in 1 ml of 0.05M Tris•HC1 pH 7.5 buffer, a sidearm containing 
25 ul of 10 mM PCA and a buret containing HINANO (774 pM) in the same buffer. 
The system was made anaerobic by 6 cycles of evacuation and repressurizing with 
argon. After recording the spectrum of native enzyme, the substrate was tipped 
in and the anaerobic E•S complex was recorded. A total of 150 pl of anaerobic 
HINANO solution was added from the buret and the spectrum of the E•I complex 
was recorded after a 30 min wait. The system was opened, compressed air was 
bubbled through the E•I complex and the aerobic spectrum was also recorded. 
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RESULTS  
Spectral Study of the Anaerobic PCD•HINANO Complex  
We have previously reported that HINANO, which possesses all the essential 
elements of the postulated transient species (VI), is the most potent inhibitor 
known for PCD (May etal.,1982).Since the spectral change observed when HINANO binds to 
the enzyme is similar to an "ES0 2 " intermediate reported by Bull et al .(1981) 
it seemed possible that it could reflect formation of a ternary EIO 2 complex. 
This possibility was tested by preparing the PCD•HINANO complex under both 
anaerobic and aerobic conditions as described in Materials and Methods. 
In the anaerobic experiments, substrate was first added to the anaerobic 
PCD solution in order to confirm formation of the characteristic E•S spectrum which 
would not have been observed inthe presence of oxygen (Fujisawa et -a1 ., 1971). HINANO 
was then added causing complete displacement of substrate and formation of 
the spectrum characteristic of the PCD•HINANO complex. It was evident that the 
spectrum of this complex is identical to that observed under aerobic condi-
tions, thus establishing that the formation of a ternary PCD•HINAN0.0 2 complex 
is not responsible for the characteristic spectral change. 
Inhibition by Pyridine N-Oxides  
Table I lists the apparent K I 's obtained for a series of pyridine N-oxides 
which differ in their pattern of ring substitution. The apparent K i 's listed 
were obtained under normal conditions for ground-state inhibitors, i.e., 
measurement of initial rates without preincubation of the enzyme and inhibitor. 
It is apparent from these values that lack of either the carboxylate or the 
ketonized m-hydroxyl causes a drastic decrease in binding affinity of more 
than 2 orders of magnitude. Furthermore, altering the para relationship of 
-13- 
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the N-oxide and carboxylate functionalities also greatly reduces inhibitor 
potency. Unexpectedly, INANO is a better inhibitor than CINANO; whereas, 
the opposite is true for the halohydroxybenzoates (May & Phillips, 1979). 
Taken together, the overall trends observed are in accord with what 
would be expected for compounds which mimic transient species along the re-
action pathway, the essential features being carboxylate, p-oxygen available 
for iron ligation and ketonizable m-oxygen. 
Time Dependence of Inactivation by Pyridine N-Oxides  
During investigations of the time dependence of PCD inhibition by the 
pyridine N-oxides listed in Table I, it became immediately apparent that 
inhibition by HYPNO is not rapidly reversible. As shown in Figure lA when 
PCD was preincubated with excess HYPNO and then diluted into an assay solu-
tion, a time dependent loss of PCD activity was observed. In these experi-
ments the enzyme •HYPNO mixture was diluted 120 fold, and the assay mixture 
contained a 450 to 4500-fold excess of substrate, and thus rapid ly 
reversible inhibition would not be seen. In contrast, when similar experi- 
ments were carried out with INANO, NANO, and CINANO at a 4:1 ratio of inhibitor 
to active sites in the preincubation mixture, no loss of activity was ob-
served as expected for inhibition which is rapidly reversible. As a check, 
a similar experiment was performed with 3-FHB, a highly potent halohydroxy - 
benzoate inhibitois whose inhibition is known to be freely reversible(Mayetal.,1978); 
similarly no inhibition was observed, as shown in Figure 2A. It is thus evi- 
dent that the presence of a ketonizable 2-hydroxy group makes inhibition much 
less reversible, and a simple Michaelis-Menten treatment is insufficient to 
describe the interaction of HYPNO with PCD. 
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It is evident from Figure lA that both the rate and extent of time de-
pendent inactivation are dependent on HYPNO concentration with inactivation 
going to near completion at ratios of 20:1 and 40:1 HYPNO to enzyme active 
sites. However, at a 4:1 ratio inactivation does not go to completion, 
thus differing from the inactivation of HINANO which causes rapid complete 
inactivation even at a ratio of 1 :1 HINANO to active sites (Mayetal., 1982). 
This implies that, in contrast to HINANO, HYPNO inactivation might be rever-
sible by dialysis. Indeed, when an enzyme solution which had been inacti-
vated by a 35:1 ratio of HYPNO to active sites was placed in an ultra-
filtration cell and 10 volumes of buffer passed through, a regain of 47% 
of control activity was observed. Thus inactivation by HYPNO is intermedi-
ate between the kinetically irreversible inhibition caused by HINANO and the 
freely reversible binding of the halohydroxybenzoates• As expected, semi-log 
plots of the inactivation data (Figure 1B) therefore deviate from linearity 
in contrast to that for HINANO inactivation. 
If it is assumed that the leveling in the 4:1 inactivation curve of 
Figure lA reflects equilibration of slowly reversible HYPNO binding, an 
equilibrium constant can be calculated from the final extent of inactivation, 
assuming KD = • E] [HYPNO] . The results of such a calculation is a KD of 
[E•HYPNO] 
4.2 x 10-6M. A K I for HYPNO inhibition was also obtained using the method 
developed by Henderson (1972), which has recently been applied to transition 
state analogs by Frieden et al.(1980)• Assuming this treatment is valid for 
the slowly reversible HYPNO binding, and usi ng the form of the 
Henderson equation appropriate for competitive inhibition, the IC I calculated 





If the inactivation described above is due to interaction of HYPNO 
with the enzyme active site, then a freely reversible ground state analog 
such as 3-FHB should be capable of protecting against the inactivation due 
to HYPNO. As shown in Figure 2A, 3-FHB does indeed protect against inacti- 
vation. Moreover, the addition of 3-FHB to the HYPNO-inactivated PCD causes 
reactivation in a first order manner as shown in Figure 2A and 2B. The first 
order rate constant for the reactivation is 4.3 x 10 -4 sec
-1
. 
Spectral Studies with HYPNO  
The results discussed to this point establish that HYPNO binds to the 
active site of PCD in a slowly reversible manner. From the initial rates of 
the inactivation of Figure 1, a second order rate constant for HYPNO binding 






can be calculated which contrasts sharply with the k
on 
of 2 x 10
6 
M
-1 sec -1 which we have previously reported for 3-FHB (May&Phillips 1979). We 
therefore proceeded to examine the spectral characteristics of HYPNO binding 
and to attempt to determine a koff for the dissociation of HYPNO from PCD, 
in order to make a direct comparison with halohydroxybenzoate and HINANO 
binding. 
When HYPNO at a 10 fold excess over active sites is added to the enzyme, 
and a spectrum taken after 30 minutes, the visible absorbance maximum is 
shifted to 485 nm as shown in Figure 3A. The absorbance change at 437 nm 
was followed and second order rate constants were calculated from the initial 





at 10:1, and 76 M-1 sec
-1 
at 20:1 give an average value of 
1.1 x 102 M-1 sec-1 which is in good agreement with the second order rate 
constant of 1 x 10 2 M-1 sec -1 calculated from the inactivation data of 
Figure 1. Thus, we conclude that both the spectral change and the inactiva-
tion reflect the same process. 
-16- 
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The determination of koff 
for the PCD•HYPNO complex was attempted by 
displacement with an excess of the inhibitor, 3-FHB. However, as can be 
seen in Figure 3A, the changes are more complex than those expected for asimpledis- 
placement(Gutfreund, 1972). Addition of a 25 fold excess of 3-FHB to the 
equilibrated PCD-HYPNO solution shows little immediate change in the 
420 nm region but a rapid significant decrease in absorbance at longer wave-
lengths. Later scans show a slow increase in the 420 nm region, with the 
final spectrum resembling that characteristic of the PCD-3-FHBamplex(Mayetal.,1978). 
As shown in Figure 3B, when this slow spectral change is followed at 
425 nm, .a linear first order plot is obtained. The first order rate con- 
stant obtained froc this plot is 2.4 x 10
-4 
sec 	which is similartothefirst order 
rate constant for t)p reactivation of PCD•HYPNO by the addition of 3-FHB 
(Figure 2) obtained under similar conditions. The rapid long wavelength 
change was also examined using stopped-flow techniques. When this rapid 
phase was examined at 570 nm under conditions of 2.5:1 3-FHB to HYPNO, a 
first order plot is obtained as shown in Figure 4. Under these conditions 
the rapid change is essentially complete in 15 sec. The first order rate 
constant calculated from the data in Figure 4 is 0.2 sec
-1
. 
The effects of 3-C1HB, a halohydroxybenzoate inhibitor which is some-
what less potent than 3-FHB(May&Phillips,1979),onthe PCD.HYPNOcomplexwre also 
examined. As can be seen in Figure 5A , there is a similar rapid spectral 
charge at long wavelengths followed by a slow increase in the 420 nm region. 
In the case of 3-C1HB the distinction between the rapid and slow processes 
is much clearer, since at long wavelengths the rapid process is characterized 
by a decrease in absorbance, and the slow process is characterized by an 
increase. The slow change followed at 420 nm gives a linear first order 
-17- 
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plot (Figure 5B) with a first order rate constant of 1.5 x 10-4 sec -1 , similar 
to that obtained with 3-FHB. It can also be seen that the final spectrum in-
dicates that the enzyme is not totally in the form of PCD•3-C1H8, as is 
evident from the spectrum of this complex shown in Figure 5A. 
Taken together, the data obtained with both 3-FHB and 3-C1HB indicate that 
two distinct events occur when these hydroxybenzoate inhibitors interact with 
the preformed PCD•HYPNO complex. A very rapid spectral change is observed 
first at long wavelengths, followed by a slower process characterized by 
changes in the 420 nm region at a rate similar to that observed in the re-
activation experiments. There are two obvious possibilities to explain these 
observations. The first requires the following assumptions: HYPNO 
binds to PCD causing the enzyme to adopt an altered conformation, PCD - . 
HYPNO can then rapidly dissociate from PCD - , and halohydroxybenzoate can also 
bind rapidly to this conformation, thus accounting for the rapid spectral 
change observed. Subsequently, the PCD - halohydroxybenzoate complex under-
goes a slow conformational change to give the normal ground state complex 
with normal spectral properties. The second possibility, which may also involve 
conformationally altered states of PCD, differs from the above in that it allows 
formation of a ternary complex. Halohydroxybenzoate inhibitor would thus bind 
rapidly to PCD•HYPNO to give this ternary complex, thus accounting for the rapid 
spectral change. Subsequent slow release of HYPNO would lead to formation of 
the normal PCD•3-FHB complex and recovery of activity. Therefore, dialysis ex-
periments were carried out to distinguish between these possibilities. 
Dialysis Experiments 
The two possibilities just mentioned to account for the spectral data 
differ in that the first implies very rapid release of HYPNO and binding of 
halohydroxytenzoate; whereas, the second possibility implies a much slower 
release of HYPNO with a half-life of approximately 50 minutes. Thus, these 
two possibilities should be clearly distinguishable in dialysis experiments 
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designed to determine which species are bound to the enzyme immediately after 
addition of the halohydroxybenzoate to the enzyme•HYPNO complex. 
A solution containing equimolar HYPNO and enzyme active sites was allowed 
to come to equilibrium, either 3-FHB or 3-C1HB was added, and the solution was 
immediately subjected to ultrafiltration. The concentrations of free HYPNO 
and halohydroxybenzoate in the effluent were then determined spectrophoto-
metrically. The results obtained under various experimental conditions are 
shown in Table II. It should be noted that approximately 3-4 minutes were 
required to obtain effluents in these experiments, which corresponds closely 
to the time elapsed at the end of the spectral scans designated with triangles 
in Figures 3A and 5A. Four primary observations can be made from the data 
in Table II. 
1. Stoichiometric binding of 3-FHB to the enzyme is observed with a 2.5 fold 
excess of 3-FHB. 
2. Greater than 1:1 binding of total inhibitor (halohydroxybenzoate + HYPNO) 
to active sites is always observed. 
3. The amount of HYPNO bound to enzyme is unaffected by the quantity of 
3-FHB bound. 
4. The amount of HYPNO bound to PCD is unaffected by the use of different 
halohydroxybenzoate inhibitors. 
Taken together, these results are consistent with formation of a ternary com-
plex, and a minimal scheme incorporating such a complex is shown in Scheme II. 
HYPNO  
	













Direct support for the postulated ternary complex is provided by the 
results of the dialysis experiments which established greater than stoichio-
metric binding of total inhibitor to the enzyme. Moreover, it is obvious 
from the spectral studies that the rapid process leads to formation of some 
complex which is spectrally distinct from either the enzyme•HYPNO complex or 
the normal enzyme•halohydroxybenzoate complex. This is accounted for by 
rapid formation of the ternary E•HYPN0.3-FHB complex. On the other hand, 
the slow process seen in the spectral studies represents dissociation of HYPNO 
from the ternary complex to form E•3-FHB, and this is fully consistent with 
the slow appearance of the characteristic E•halohydroxybenzoate complex. 
Assuming this minimal scheme, values can be assigned to the various rate 
constants from the results of our spectral and inhibition experiments, and 
these values are listed in Table III. The value for k 1 
is obtained from the 
inactivation data in excellent agreement with that obtained from direct 
spectrophotometric measurement of HYPNO binding. The value of K D (1) , the 
dissociation constant for HYPNO binding given by k 2/kl , is obtained from 
the extent of HYPNO inactivation at equilibrium (Figure 1). It is interesting 
that this value agrees well with the kinetically determined KIHYPNO  obtained 
using the Henderson analysis, but differs markedly from the value obtained 
from a simple Michaelis-Menten treatment. With these values in hard, the 
magnitude of k 2 is calculated directly as approximately 3 x 10
-4 
sec
-1 , which 
is in accord with our expectation that HYPNO dissociation should be a slow 




are obtained from the rates of the rapid and 
slow spectral changes, respectively (Figures 3 and 4). An internal check 
on the value of k
5 
is provided by the 3-FHB reactivation data (Figure 2). 
Under the conditions of this experiment, the magnitude of k 3 predicts that 
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the ternary complex should be formed rapidly and the reactivation process actu- 
ally reflects k 5 . There is, in fact, good agreement between the values of k 5 
obtained from these two sets of experiments. The values listed for k 7 and k 8 
are taken from our previous results with halohydroxybenzoate inhibitors (May & 
Phillips, 1979). 
The results of the dialysis experiments provide a value for KD (2) , the 
dissociation constant for 3-FHB release from the ternary complex, since under 
the conditions of these experiments, ternary complex formation is essentially 
complete, and the extent of HYPNO dissociation (k 5 ) is negligible. The 
concentrations of free 3-FHB and HYPNO therefore provide a measure of the 
magnitude of KD (2) , calculated as described in the Methods Section. This 
value is found to be 16 x 10 -6M and a similar calculation from the data for 
3-C1HB provides a value of 48 x 10
-6M for K
D
(2) of this compound. 
Further support for Scheme II is provided by the following: The 
spectral studies predict that under the conditions of the dialysis experi-
ments the fast process should be essentially complete and the slow process 
should not hEve Legun. This is supported by the dEta in Table II which shows 
that the amount of HYPNO bound to the enzyme is not affected by either 
the identity or quantity of the halohydroxybenzoate inhibitor. Therefore, 
the amount of HYPNO bound reflects only the equilibrium position of the 
initial binding process, and a value of KD (1) should thus be obtainable 
from the measured amount of free HYPNO and the kncwn initial concentrations. 
According to this reasoning, the value of KO (1) calculated from these data 
should agree with that determined independently from the extent of inacti-
vation at equilibrium (Figure 2). As shown in Table III this is, in fact, 
the case. It is important to note that the value obtained from K D (1) in 
this manner is independent of whether 3-FHB or 3-C1HB is used in the dialysis 
experiments, and this provides strong support for interpretation of our data 
in terms of Scheme II. However, it should be noted that this is a minimal scheme 
-21- 
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which does not distinguish between different conformational states of PCD. 
Reactivation by Dilution  
Since the rate of dissociation of HYPNO from PCD•HYPNO could not be 
determined by displacement because of the formation of a ternary complex, 
reactivation by dilution was carried out. Schloss and Cleland (1982) have 
recently used this method to determine the upper limit of a dissociation 
rate constant for isocitrate lyase complexed tc the reaction-intermediate 
anElog, 3-nitropropionate. When a concentrated enzyme•HYPNO solution is 
diluted 1000 fold into an assay solution containing 400 pm PCA a slow 
increase in activity is seen, as shown in Figure 6. The final maximum rate 
is extrapolated beck to the x-axis. The reciprocal of the x-axis value at 
the extrapolated line intersection is equal to k, the dissocation rate con- 
stant, if reactivation goes to completion. Since the final rate is only 53% of 
the uninhibited rate due to substrate depletion, the value obtained, 
k




, is an upper limit for the dissociation rate constant. 
This value is clearly consistent with the calcclated values for k 2 in Table III. 
Inactivation by MINANO  
The data in Table I establishes that various pyridine N-oxides are capable 
of interacting with protocatechuate 3,4-dioxygerase, but as discussed above, 
the presence of a ketonizable 2-hydroxy group in HYPNO and HINANO results in 
inhibition which is not freely reversible. We were therefore interested in 
examining the affect of a 2-sulfhydryl substituent on pyridine N-oxide inhi-
bition, since this functionality would also be e).pected to exist primarily in the 
keto form (Jones & Katritzky, 1960). As shown in Figure 7, incubation of the 
enzyme with MINANO followed by dilution into an excess of assay solution results 
in time dependent inhibition of the type observed previously for HYPNO (Figure 1A). 
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Since rapidly reversible inhibition would not be seen under these conditions, 
it is evident that the presence of a 2-thio substituent does indeed interefere 
with reversibility. The data in Figure 7 indicate that both the rate and 
extent of inhibition are dependent on MINANO concentration, with inhibition 
going to completion at a ratio of 4:1 MINANO to active sites. This contrasts 
with the oxygenated analog, HINANO, where inhibition goes rapidly to completion at 
ratios of 1:1 (May et al.,1982). As expected, MINANO is a considerably more 
potent inhibitor than HYPNO, since the former possesses a carboxyl moiety which 
presumably interacts at the cationic site which binds the carboxyl of the 
normal substrate. However, it is clear that although the carboxyl affects 
inhibitor potency it is the presence or absence of a ketonizable substituent 




The interaction of PCD with various halohydroxybenzoate ground state inhi-
bitors has been previously studied in this and other laboratories (May et al., 
1978; May & Phillips, 1979; Felton et al, 1978; Fujisawa et al, 1971; Fujisawa 
et al., 1972a;Fujisawa etal.,1972b; Que et al.,1977; Keyes et al., 1978; Tatsuno 
et al • ,1978; Nakata et al.,1978). For example, we have reported that the most 
potent of the halohydroxybenzoate inhibitors, 3-FHB, binds stoichiometrically to 
the enzyme; however, its inhibition is rapidly reversible and is not apparent when 
the complex is diluted into a large excess of substrate. The halohydroxybenzoates, 
3-FHB and 3-C1HB, also give a spectral change upon binding to PCD which is charac-
terized by a shift of the visible maximum from 450 to 420 nm. This characteristic 
shift occurs under both aerobic and oxygen deficient conditions (May et al.,1978). 
The behavior of the halohydroxybenzoates contrasts with that of HINANO, a 
compound designed to mimic the ketonized form of the PCD substrate, PCA. As we 
have previously reported (May et al., 1982), HINANO binds stoichiometrically to 
the active site of PCD but does so in an essentially irreversible manner, being 
released only after denaturation of the enzyme. HINANO is an excellent active 
site titrant and is capable of completely displacing the most potent halohydroxy-
benzoate, 3-FHB, from the active site; whereas, even an excess of 3-FHB does not 
displace HINANO. The PCD•HINANO complex exhibits spectral properties resembling 
those of an advanced intermediate along the substrate reaction pathway (Bull , 
et al., 1981). However, due to the irreversibility of HINANO binding, a detailed 
kinetic study using standard techniques was not feasible. 
The data presented in this paper establish that HYPNO, which has the same 
2-hydroxypyridine N-oxide structure as HINANO but lacks the carboxyl, is also 
not a freely reversible inhibitor, thus differing from the halohydroxybenzoates. 
However, we have found that HYPNO inhibition, unlike that of HINANO,is slowly 
reversible, thus allowing a complete kinetic characterization of its inter-
action with POD. Cur results allow a direct comparison of the rate constants 
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for binding and dissociation of HYPNO with those for 3-FHB. The Ic on for HYPNO 


















 and the k
off 
for 3-FHB is approximately 1 sec -1 . Thus, both binding and dissoci-
ation rate constants are four orders of magnitude less for HYPNO. Although the 
K
D 
value for 3-FHB (0.5 x 10
-6
M) is less than that for HYPNO (3 x 10
-6M) im-
plying comparable binding of the former, the low values of the on and off rate 
constants for HYPNO are responsible for this compound exhibiting time dependent 
inactivation which is only slowly reversed by dilution or dialysis. 
It is clear from studies with other enzymes, such as adenosine deaminase 
and adenylate deaminase, that transition state analogs characteristically appear 
to have "on" rate constants which are considerably smaller than those expected 
for diffusion-controll processes (Frieden et al.,1980; Wolfenden, 1976; Kurz & 
Frieden, 1983). For example, the Ic on values for various coformycin analogs to 





-1 . These values are quite 
similar to those which we have previously reported for HINANO binding to PCD 
(May et al.,1982). By comparison, the k on for HYPNO is about 2 orders of magni-
tude slower. This is not unexpected, since HYPNO lacks the carboxylate functionali-





for HYPNO is also very similar to the values reported 
for the coformycin analogs. Therefore, it seems clear that the presence of the 
ketonizable 2-hydroxy group and the hydroxamic acid-like p-oxygen which is an 
excellent iron ligand (Neilands, 1966; Chatterjee, 1978), are sufficient to 
confer the "transition-state analog-like" characteristics of slow binding and 
dissociation on PCD inhibitors. The other pyridine N-oxides studied (Table I) 
which lack these features do not exhibit these characteristics. On the other 
hand, MINANO with a ketonizable 2-thiol substituent, does exhibit the characteristics 
of HINANO and HYPNO inhibition. 
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The results of our spectral and dialysis experiments on the interactions 
of halohydroxybenzoates with the E•HYPNO complex are consistent with formation 
of a ternary E•HYPN0.3-XHB complex. There is no precedent for formation of 
such a ternary complex in all pr evious studies with PCD inhibitors and sub-
strate analogs, and thus this result was unexpected. On the basis of infor-
mation in the literature regarding binding interactions at the PCD active 
site, it is tempting to speculate about a possible physical explanation for 
this result. One can visualize that in the case of substrate and halohydroxy-
benzoate inhibitors since binding involves both ligation of the para hydroxyl 
and ionic interaction of the carboxylate with a cationic group of the enzyme--
likely an arginine -- (May & Phillips, 1979; Carlson et al., 1980), the active 
site is pinned into a closed conformation. An additional substrate or inhibitor 
molecule cannot be accommodated in this conformation and ternary complexes do 
not occur. However, upon binding of HYPNO which contains a potent iron-ligating 
functionality but no carboxyl, the cationic site may remain sufficiently accessible 
to interact with the carboxylate of a 3-XHB molecule without immediate ligation 
of its para hydroxyl. 
It should be noted that Scheme II represents a minimal scheme which should 
be regarded at this point as a working hypothesis on which to base further experi-
ments. As indicated in Table III, assumotion of this scheme results in very 
good internal consistency between the various rate and equilibrium constants 
obtained from inactivation, spectral, and dialysis experiments. However, 
different conformational states of PCD are not taken into account and the 
values for several of the rate constants have not been independently confirmed. 
Thus, the actual detailed pathway for formation and decomposition of the postu-
lated ternary complex could be considerably more complex. 
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Previous resonance Raman investigations in this laboratory (Felton 
et al.,1978) and by Que and Epstein (1981) have provided evidence for the 
direct ligation of the para hydroxyl of hydroxybenzoate inhibitors to iron 
at the active site of PCD. These studies have also shown the presence of 
two tyrosine ligands which are not displaced upon substrate or inhibitor binding. 
Recent studies from our laboratory using resonance Raman and extended X-ray 
absorption fine structure (EXAFS) have provided further insight into the ligation 
environment at the site of PCD (Felton et al.,1982). These studies have 
provided evidence for the presence of two histidine ligands, one of which is 
displaced upon binding of the halohydroxybenzoate, 3-C1HB. Thus, as has been 
previously suggested, histidine may become available to act as a general base, 
providing for the removal of even relatively nonacidic p-hydroxyl protons (such as 
those found in all PCD substrates), as the hydroxyl nears the coordination 
sphere of iron. In view of the spectral differences seen between the halo-
hydroxybenzoate and HINANO or HYPNO complexes with PCD, it will be interesting 
to see whether EXAFS studies are capable of revealing ligation differences 
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ENZYME INHIBITOR DIALYSIS EXPERIMENTS6 
Halohydroxybenzoate Ratio of 
Inhibitor 	 Halohydroxybenzoate  : HYPNO:PCD Active  Sites 
Initial b 	 Bound 
3-FHB 
	










Expt. 2 0.59:0.66:1 
C-C1HB 	 1:1:1 
	
0.43:0.74:1 
aHYPNO was incubated with the enzyme for 30 minutes at room temperature 
followed by addition of 3-FHB or 3-C1HB and immediate ultrafiltration. 
The filtration was complete 3-4 minutes after the addition of 3-FHB 
or 3-C1HB. See Materials and Methods for details. 
bT
he actual initial concentrations for 3-FHB, 2.5:1:1 were Expt. 1: 
[HYPNO]=[enzyme active sites] = 24.2 x 10-6 M and [3-FHB] = 60.4 x 10 -6 M, 
Expt. 2: [HYPNO] = [enzyme active sites] = 26.4 x 10 -6 M and [3-FHB] = 
65.8 x 10
-6 
M; for 3-FHB, 1:1:1, Expt.1: - [3-FHB] = [HYPNO] = [enzyme active 
sites] = 26.6 x 10 -6 M, Expt. 2: [3-FHB] = [HYPNO] = [enzyme active sites] = 
25.6 x 10-6 M; and for 3-C1HB, 1:1:1, [3-C1HB] = [HYPNO] = [enzyme active 
sites] = 26.6 x 10 -6 M. 
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TABLE III 

































K 	1.6 x 10
-6 M 
KD(1)




























-1 h from Ternary 
Complex 
0.5 x 10





 M -1 sec -1 i 





a Calculated from initial rates of inactivation 
b Calculated from initial rates of spectral change 
c Calculated from k 1 
K
I 




value from equilibrium inactivation data 
e Calculated from results of the stopped-flow study of the fast spectral change 
f Calculated from k 3 K D 
g Calculated 3•FHE reactivation data 
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Table III (footnotes continued) 
h Calculated from the slow spectral change initiated by 3-FHB addition 
i 	See (May & Phillips, 1979). 
j Calculated from the Henderson Plot 
k Calculated from equilibrium inactivation data 
I Calculated from the dialysis 1:1:1 experiments with 3-FHB 
m Calculated from the 1:1:1 dialysis experiment with 3-C1HB 
n Calculated from the 1:1:1 dialysis experiments with 3-FHB (average of 




FIGURE 1  
TIME DEPENDENT INACTIVATION OF ENZYME BY HYPNO  
(A) Time course of inactivation of the enzyme by HYPNO was followed by 
incubating at room temperature 0.5 ml of 0.331 pM enzyme (2.65 uM enzyme 
active sites) in 0.05 M Tris•HC1, pH 7.5 at 25 °C, which was 10.6 uM (o), 
53 pM (A), and 106 pM( ❑) in HYPNO giving ratios of 4:1 (0), 20:1 (L), and 
40:1 ( ❑ ) HYPNO : enzyme active sites. These solutions were assayed by 
adding 25 ul to 3 ml of an assay solution containing 300 ul of 0.5 M Tris•HC1, 





C with a DW-2 spectrophotometer (Aminco). Initial 
rates of decrease in [protocatechuic acid] were calculated using c = 2280 M -1 
 cm
-1 
and compared to a control solution containing no HYPNO which retained full 
activity throughout the inactivation period. (B) First order plot of the data 
in A. Second order rate constants calculated from initial rates of inactiva- 
tion are 93.1 M -1 sec
-1 (o), 99.1 M-1 	-1 sec 	(A) and 121 M
-1 
sec
-1 ( ❑ ). 
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FIGURE 2  
3-FHB PROTECTS PCD AGAINST INACTIVATION BY HYPNO AND  
REACTIVATES HYPNO-INACTIVATED PCD  
(A) Time course of inactivation of the enzyme was followed by incu-
bating at room temperature 0.5 ml of 0.314 IA enzyme (2.51 uM enzyme active 
sites) in 0.05 M Tris•HC1, pH 7.5 at 25 °C, which was 50.2 IA in 3-FHB (0), 
50.2 uM in 3-FHB and 50.2 uM in HYPNO (A), or 50.2 uM in HYPNO followed by 
addition of 3-FHB to a concentration of 124 IN at arrow ( ❑). These incu-
bations gave ratios of 20:1 3-FHB: active sites (o), 20:20:1 3-FHB:HYPNO: 
active sites (A), and 20:1 HYPNO:active sites followed by 50:20:1 3-FHB: 
HYPNO:active sites at arrow. The assays were carried out as in Figure 1A. 
(B) First order plot of the reactivation in 2A assuming infinite reactiva-
tion to 77%. Times given are minutes following addition of 3-FHB. 
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FIGURE 3 
SPECTRAL STUDY OF ENZYME, HYPNO AND 3-FHB INTERACTIONS  
(A) Spectra were taken with a DW-2 spectrophotometer thermostated at 
25° C. The enzyme solution was 11.6 x 10 -6M in active sites in 0.05M Tris-HC1, 
pH 7.5 at 25° C, ( 	). This solution was preincubated for 30 min with 
HYPNO at a ratio of 10:1 HYPNO:active sites and scanned (---). The inhibitor 
3-FHB was then added to give a ratio of 25:1 3-FHB:HYPNO and this solution 
was scanned immediately (- A-A ), after 1.5 hours (-o-o) and after 3.5 hours 
(- ❑ -0 ). Intermediate scans were also made but omitted for the sake of 
clarity. A separate solution containing the same concentrations of only 
enzyme and 3 - FHB was scanned after 3.5 hours of preincubation ( x x x x ). 
(B) Values of A
ce - At 
at 425 nm were calculated assuming A = 0.0569 
for all scans of the solution containing enzyme, HYPNO, and 3-FHB. These 
values give a linear semilogarithmic plot. 
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FIGURE 4  
KINETICS OF THE FAST SPECTRAL CHANGE  
A solution in 0.05 M Tris•HC1, pH 7.5 at 25 ° C containing 26.6 x 10 -6 M, 
enzyme active sites and 26.6 x 10
-5
M HYPNO was preincubated for at least 
30 min before flowing against a 665 x 10-6M 3-FHB solution in the same 
buffer (final concentrations are one-half those given). The experiment 
was carried out in a DW-2 spectrophotometer (Aminco) and the fast change 
was followed at 570 nm with the reference at 750 nm. 
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FIGURE 5  
SPECTRAL STUDY OF ENZYME, HYPNO AND  
3-C1HB INTERACTIONS  
(A) This experiment was performed exactly as in Figure 3 except 3-C1HB 
was used in place of 3-FHB. The enzyme solution was scanned alone ( 	), 
after 30 min preincubation with HYPNO ( - - - ), immediately after the 
addition of 3-C1HB (- A- A), 2 hours later ( -o-o ), and 4.5 hours later 
( - 	o ). Intermediate scans are again omitted for clarity. A separate 
solution containing the same concentrations of only enzyme and 3-C1HB was 
scanned after 4.5 hours of preincubation ( x x x x). (B) Values of A co - At 
at 420nm were calculated assuming A . = 0.057 for all scans of the solution 




REACTIVATION OF ENZYME•HYPNO COMPLEX BY DILUTION  
A solution of 5.3 x 10
-6
M enzyme active sites in 0.05M Tris•HC1, pH 7.5 
at 25° C was incubated with 1.06 x 10 -4M HYPNO (20 fold excess) for 30 min. 
Three microliters of this solution were then added to 3 ml of an assay solu-
tion containing 400 x 10 -6M PCA and 0.05 M Tris•HC1, pH 7.5 at 25° C and the 
A290 was followed in a Varian DMS 90 spectrophotometer. A control solution the 
same as above, but without HYPNO, was assayed in the same manner. Both assays 
were followed to the extent of substrate depletion which began to diminish the 
reaction rate of the control. 
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FIGURE 7  
TIME DEPENDENT INACTIVATION OF ENZYME BY MINANO  
The time course of inactivation of enzyme by MINANO was followed by 
incubating at room temperature 1 ml of 2.5 x 10
-6 
to 4.0 x 10
-6 
M enzyme 
active sites in 0.05 M Tris•HC1, pH 7.5 at 25 ° C, which was 1:1 (o) 2:1 
(A) and 4:1 (0) in the ratio of MINANO to enzyme active sites. These 
solutions were assayed as described in Figure 1 except 20 ul of the 4:1 
solution was added to the assay mixture and the A 290 was followed on a 
Varian DMS 90 spectrophotometer. 
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